Better.com Launches Loyalty Rewards Program to Provide Lifetime Savings for Homeowners
NEW YORK, February 05, 2025--(BUSINESS WIRE)--Better Home & Finance Holding Company (NASDAQ: BETR) ("Better.com") ("Better Mortgage") the leading digital homeownership company, today announced the launch of Better Forever, a loyalty initiative designed to reward customers with waived origination fees on future refinance or purchase loans.
The launch of this program marks a new chapter in Better's mission to make homeownership easier and more affordable. Customers who funded a loan with Better Mortgage on or after January 1, 2019, are automatically enrolled, while those buying a new home will also have the benefit of a waived originations fee through the Better Forever program.
With a more favorable interest rate environment anticipated in 2025, Better Forever is designed to maximize savings for customers while deepening trust and loyalty. By providing unmatched lifetime value and the ability to leverage future rate drops, the program empowers homebuyers to optimize their financial goals through Better's seamless, fully digital homeownership platform.
"We are proud to continue delivering on our promise of being a digitally-native homeownership company that remains customer-first – especially at a timely moment for consumers across the country," said Vishal Garg, CEO & Founder of Better. "Homeowners deserve to feel confident in the interest rate tied to their mortgage for the life of their loan, not just when they complete their transaction. With Better Forever, we can help borrowers begin benefitting from their purchase or refinance today, without the fear of missing out on a better rate tomorrow."
To learn more about the Better Forever program, users can access Betsy™, the industry's first voice-based AI loan assistant designed to improve the customer experience with more intelligent, timely and accurate answers to inquiries on an instant basis, 24/7/365 or visit better.com/b/better-forever.
Terms apply. Eligible customers include those who have previously originated and funded a purchase, refinance, or home equity loan through Better Mortgage. The Better Forever program applies to (1) the refinancing of a loan originally secured with Better Mortgage for the same property and under the same name or (2) the purchase of a new property after securing a loan with Better Mortgage. Future second lien, home equity loans, loans secured through third-party platforms and refinances within six months of a customer's last funded loan are ineligible for the Better Forever Program. Please review full Better Forever Terms and Conditions on https://better.com/b/better-forever#ts&cs.
About Better.com
Since 2017, Better Home & Finance Holding Company (NASDAQ: BETR; BETRW) has leveraged its industry-leading technology platform, Tinman™, to fund more than $100 billion in mortgage volume. Tinman™ allows customers to see their rate options in seconds, get pre-approved in minutes, lock in rates, and close their loan in as little as three weeks. Better's mortgage offerings include GSE-conforming mortgage loans, FHA and VA loans, and jumbo mortgage loans. Better launched its "One Day Mortgage" program in January 2023, which allows eligible customers to go from click to Commitment Letter within 24 hours. Better was named Best Online Mortgage Lender by Forbes and Best Mortgage Lender for Affordability by WSJ in 2023, ranked #1 on LinkedIn's Top Startups List for 2021 and 2020, #1 on Fortune's Best Small and Medium Workplaces in New York, #15 on CNBC's Disruptor 50 2020 list, and was listed on Forbes FinTech 50 for 2020. Better.com serves customers in all 50 US states and the United Kingdom.
For more information, follow @betterdotcom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205736575/en/
Contacts
Better@avenuez.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Sidus Space Reports Second Quarter 2025 Financial Results and Provides Business Update
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Sidus Space (NASDAQ: SIDU), (the 'Company' or 'Sidus'), an innovative space and defense technology company, today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. The Company is scheduled to host a conference call and webcast today, Thursday, August 14, at 5:00 p.m. ET. 'Q2 was about disciplined execution and building durable technology assets. We advanced LizzieSat®‑3 commissioning, fully staffed our 24/7 Mission Operations Center, and expanded our proprietary platform with the Fortis™ VPX Command and Data Handling system and Orlaith™ AI Ecosystem, built to move data and insights seamlessly across space, air, land, and sea,' said Carol Craig, Sidus Chairwoman and CEO. 'We invested ahead of revenue to build core IP and capability. As we enter the second half of the year, we're prioritizing commercialization, aligning spend to milestones, and pursuing capital‑efficient ways to turn our technology into revenue.' Operational Highlights for the Quarter Ending June 30, 2025: Completed commissioning of the ADCS system on LizzieSat®-3 with cutting-edge Autonomous, Machine-Learning-Powered on-board GNC software Fully staffed our in-house Mission Operations Center, enabling 24/7 spacecraft monitoring Received Notice of Allowance for our Modular Satellite Platform—a patent that safeguards the intellectual property behind our adaptable and scalable satellite architecture Deployed Orlaith™ AI system in Asia strengthening global AI and analytics offerings Amended and extended the lunar satellite manufacturing contract with Lonestar Holdings, bringing the total potential value to $120 million Continued building and delivering space and defense hardware for commercial and government customers Subsequent Operational Highlights: Designed LizzieLunar™ to address the Moon's unique operational challenges Successfully executed a capital raise to fund key technology initiatives, including dual-use, multi-domain Fortis™ VPX product line, which supports applications across air, land, sea and space Appointed Tiffany Norwood, Founder and CEO of Tribetan and a globally recognized serial entrepreneur and technology pioneer, to the Board of Directors Financial Highlights for the Second Quarter Ending June 30, 2025: Revenue: $1.3 million, up 36% compared to $928,000 in Q2 2024, reflecting a strategic pivot away from legacy services to new commercial models Cost of Revenue: $2.3 million, up 29% from Q2 2024 due to increased satellite and software depreciation and an increase of material and labor costs Gross Profit (Loss): $(1.0) million, compared to $(841,000) loss in Q2 2024 due to reduced contribution from legacy high-margin services as we transition to higher-value, recurring revenue lines SG&A Expenses: $4.3 million, up from $3.1 million in Q2 2024, driven by headcount growth, launch rescheduling, and operational scaling Adjusted EBITDA: Loss of $3.9 million (non-GAAP), compared to a $3.2 million loss in Q2 2024 Net Loss: $5.6 million, versus $4.1 million in Q2 2024, driven by strategic investment and depreciation Cash Position: $3.6 million as of June 30, 2025, versus $1.4 million a year earlier Conference Call and Webcast Event: Sidus Space Second Quarter Financial Results Conference Call Time: 5:00 p.m. Eastern Time Live Call: + 1-877-269-7751 (U.S. Toll-Free) or +1-201-389-0908 (International) Webcast: For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, August 28, 2025, at 11:59 P.M. ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13755242. An online archive of the webcast will be available for three months following the event at About Sidus Space Sidus Space (NASDAQ: SIDU) is an innovative space and defense technology company offering flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space system and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida's Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Sidus Space's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Non-GAAP Measures To provide investors with additional information in connection with our results as determined in accordance with GAAP, we use non-GAAP measures of adjusted EBITDA. We use adjusted EBITDA in order to evaluate our operating performance and make strategic decisions regarding future direction of the company since it provides a meaningful comparison to our peers using similar measures. We define adjusted EBITDA as net income (as determined by U.S. GAAP) adjusted for interest expense, depreciation and amortization expense, acquisition deal costs, severance costs, capital market and advisory fees, equity-based compensation and warrant costs. These non-GAAP measures may be different from non-GAAP measures made by other companies since not all companies will use the same measures. Therefore, these non-GAAP measures should not be considered in isolation or as a substitute for relevant U.S. GAAP measures and should be read in conjunction with information presented on a U.S. GAAP basis. The following table reconciles adjusted EBITDA to net loss (the most comparable GAAP measure) for the three months ended June 30, 2025 and 2024: (i) Sidus Space incurred increased interest expense due to short-term note payable due in Q4 2024 and interest expense related to an asset based loan. (ii) Sidus Space incurred increased depreciation expense 2025 and 2024 with launch and deployment of satellite fixed asset and related satellite software, as well as new ERP software capitalization. (iii) Sidus Space incurred increased equity based compensation expense due to incentive programs implemented by the Board in 2025. Expand SIDUS SPACE, INC. CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 Assets (Unaudited) Current assets Cash $ 3,634,693 $ 15,703,579 Accounts receivable 873,557 827,886 Accounts receivable - related parties 1,037,606 641,376 Inventory 370,067 255,716 Contract asset 993,504 1,347,386 Contract asset - related party 107,013 46,953 Prepaid and other current assets 4,155,398 3,429,656 Total current assets 11,171,838 22,252,552 Property and equipment, net 17,179,137 14,891,976 Operating lease right-of-use assets 835,140 121,545 Intangible asset 398,135 398,135 Other assets 85,173 81,359 Total Assets $ 29,669,423 $ 37,745,567 Liabilities and Stockholders' Equity Current liabilities Accounts payable and other current liabilities $ 5,755,965 $ 3,388,667 Accounts payable and accrued interest - related party 774,600 673,743 Contract liability - 16,192 Contract liability - related party 107,013 46,953 Asset-based loan liability 7,881,629 6,902,636 Notes payable - 3,059,767 Operating lease liability 260,311 121,544 Total current liabilities 14,779,518 14,209,502 Operating lease liability - non-current 575,598 - Total Liabilities 15,355,116 14,209,502 Commitments and contingencies - - Stockholders' Equity Preferred Stock: 5,000,000 shares authorized; $0.0001 par value; no shares issued and outstanding Series A convertible preferred stock: 2,000 shares authorized; 0 shares issued and outstanding - - Common stock: 210,000,000 authorized; $0.0001 par value Class A common stock: 200,000,000 shares authorized; 18,204,483 and 15,956,816 shares issued and outstanding, respectively 1,821 1,597 Class B common stock: 10,000,000 shares authorized; 100,000 shares issued and outstanding 10 10 Additional paid-in capital 86,705,397 83,887,682 Accumulated deficit (72,392,921 ) (60,353,224 ) Total Stockholders' Equity 14,314,307 23,536,065 Total Liabilities and Stockholders' Equity $ 29,669,423 $ 37,745,567 Expand SIDUS SPACE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue $ 691,070 $ 834,798 $ 851,774 $ 1,679,909 Revenue - related parties 569,953 92,772 647,743 297,816 Total - revenue 1,261,023 927,570 1,499,517 1,977,725 Cost of revenue 2,288,165 1,768,671 4,155,137 2,734,762 Gross profit (loss) (1,027,142 ) (841,101 ) (2,655,620 ) (757,037 ) Operating expenses Selling, general and administrative expense 4,263,269 3,056,814 8,707,711 6,702,397 Total operating expenses 4,263,269 3,056,814 8,707,711 6,702,397 Net loss from operations (5,290,411 ) (3,897,915 ) (11,363,331 ) (7,459,434 ) Other income (expense) Other income - 1,613 - 1,613 Interest expense (2,546 ) (186,175 ) 22,047 (339,701 ) Interest income 27,979 12,313 94,324 12,313 Asset-based loan expense (360,092 ) (65,920 ) (792,737 ) (161,375 ) Total other income (expense) (334,659 ) (238,169 ) (676,366 ) (487,150 ) Loss before income taxes (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Provision for income taxes - - - - Net loss (5,625,070 ) (4,136,084 ) (12,039,697 ) (7,946,584 ) Dividend on Series A preferred Stock - - - (42,375 ) Net loss attributed to stockholders $ (5,625,070 ) $ (4,136,084 ) $ (12,039,697 ) $ (7,988,959 ) Basic and diluted loss per common share $ (0.31 ) $ (0.99 ) $ (0.66 ) $ (2.32 ) Basic and diluted weighted average number of common shares outstanding 18,320,025 4,181,344 18,274,485 3,450,577 Expand Six Months Ended June 30, 2025 2024 Cash Flows From Operating Activities: Net loss $ (12,039,697 ) $ (7,946,584 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation 436,692 160,028 Depreciation and amortization 2,066,969 858,033 Non-cash fees on asset-based loan - Bad debt - - Changes in operating assets and liabilities: Accounts receivable (45,671 ) 553,764 Accounts receivable - related party (396,230 ) (197,355 ) Inventory (114,351 ) (182,757 ) Contract asset 353,882 - Contract asset - related party (60,060 ) (2,827 ) Prepaid expenses and other assets (729,556 ) 946,246 Accounts payable and accrued liabilities 2,537,168 (1,968,107 ) Accounts payable and accrued liabilities - related party 100,857 210,363 Contract liability (16,192 ) - Contract liability - related party 60,060 2,827 Changes in operating lease assets and liabilities 770 (3,699 ) Net Cash provided by (used in) Operating Activities (7,845,359 ) (7,570,068 ) Cash Flows From Investing Activities: Purchase of property and equipment (4,354,130 ) (4,067,741 ) Cash paid for asset acquisition - - Net Cash used in Investing Activities (4,354,130 ) (4,067,741 ) Cash Flows From Financing Activities: Proceeds from issuance of common stock units - 13,742,311 Proceeds from exercise of warrants 2,381,247 - Proceeds from asset-based loan agreement 4,413,239 46,133 Repayment of asset-based loan agreement (3,604,116 ) (1,772,373 ) Repayment of notes payable (3,059,767 ) (150,000 ) Net Cash provided by (used in) Financing Activities 130,603 11,866,071 Net change in cash (12,068,886 ) 228,262 Cash, beginning of period 15,703,579 1,216,107 Cash, end of period $ 3,634,693 $ 1,444,369 Supplemental cash flow information Cash paid for interest $ 630,874 $ 338,116 Cash paid for taxes $ - $ - Non-cash Investing and Financing transactions: Conversion interest and fees of asset based loan $ 169,870 $ - Class A common stock issued for conversion of Series A convertible preferred stock $ - $ 16,566 Recognition of right-of-use asset and lease liability $ 856,787 $ 284,861 Expand
Business Wire
5 hours ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
Business Wire
5 hours ago
- Business Wire
Braze to Report Fiscal Second Quarter 2026 Results
NEW YORK--(BUSINESS WIRE)--Braze (NASDAQ: BRZE), the leading customer engagement platform that empowers brands to Be Absolutely Engaging™, today announced it will release its financial results for the second quarter of fiscal year 2026, ended July 31, 2025, after U.S. financial markets close on Thursday, September 4, 2025. Braze will host a webcast conference call to discuss its financial results at 4:30 pm ET (1:30 pm PT) on the same day. The webcast will be available under the events section of our Investor site at What: Braze Fiscal Second Quarter 2026 Financial Results Conference Call When: Thursday, September 4th at 4:30 pm ET / 1:30 pm PT Webcast & Supplemental Data: A webcast replay will be accessible on our Investor site shortly after the live event. About Braze Braze is the leading customer engagement platform that empowers brands to Be Absolutely Engaging.™ Braze allows any marketer to collect and take action on any amount of data from any source, so they can creatively engage with customers in real time, across channels from one platform. From cross-channel messaging and journey orchestration to Al-powered experimentation and optimization, Braze enables companies to build and maintain absolutely engaging relationships with their customers that foster growth and loyalty. The company has been recognized as a 2024 U.S. News & World Report Best Companies to Work For, 2024 Best Small & Medium Workplaces in Europe by Great Place to Work ®, 2024 Fortune Best Workplaces for Women™ by Great Place to Work ® and was named a Leader by Gartner ® in the 2024 Magic Quadrant™ for Multichannel Marketing Hubs and a Strong Performer in The Forrester Wave™: Email Marketing Service Providers, Q3 2024. Braze is headquartered in New York with 15 offices across AMER, LATAM, EMEA, and APAC. Learn more at Disclosure Information: In compliance with disclosure obligations under Regulation FD, Braze announces material information through a variety of means, including its Investor site, press releases, SEC filings, public conference calls, and company blog posts.
